Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapyFadi Khreish, Niklas Kochems, Florian Rosar, et al.
Pharmaceutics|June 2, 2021
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor PrognosisFlorian Rosar, Jonas Krause, Mark Bartholomä, et al.
Molecular Imaging and Biology|August 29, 2020
Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) ConjugatesSebastian Martin, Stephan Maus, Tobias Stemler, et al.
BMC Neurology|May 3, 2019
18F-FDG PET/CT: an unexpected case of Huntington's diseaseSebastian Michels, Hans-Georg Buchholz, Florian Rosar, et al.
EJNMMI Research|May 26, 2020
Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patientsFlorian Rosar, Kalle Ribbat, Martin Ries, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 22, 2025
From bench to bedside, blade, and back: FAP expression in juvenile angiofibroma. Potential implications for FAPI-PET/CT imaging and targeted therapy?Lukas Pillong, Caroline Burgard, Florian Rosar, et al.
Biomolecules|August 27, 2021
Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand TherapyFadi Khreish, Mona Wiessner, Florian Rosar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2021
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)Fadi Khreish, Zaidoon Ghazal, Robert J Marlowe, et al.
EJNMMI Physics|May 5, 2021
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapyFlorian Rosar, Niklas Schön, Hendrik Bohnenberger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 2, 2021
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapyFlorian Rosar, Felix Wenner, Fadi Khreish, et al.
Pageof 10